Research groups
Colleges
Gulsah Albayrak
BSc, MSc, PhD, DPhil, FHEA
Postdoctoral Researcher
- Lecturer of MSc in Applied Cancer Science
RESEARCH SUMMARY
My research focuses on advancing our understanding of T-cell biology and its applications in cancer immunotherapy with a particular emphasis on solid tumours; those main areas:
- T-cell Exhaustion: Investigating the cellular and molecular mechanisms underlying T-cell exhaustion, a state of dysfunction that impairs anti-tumour immune responses. The goal is developing strategies to prevent/reinvigorate exhausted T-cells.
- Optimizing T-cell Engagers: Improving bispecific antibodies that redirect T-cells to tumour cells, exploring their mechanisms of action and refining their design for improved therapeutic outcomes.
By integrating these two research focuses, our aim is to translate findings into novel and more effective cancer treatments, ultimately improving patient outcomes in solid tumour malignancies.
BIOGRAPHY
Gulsah completed her DPhil in Oncology at the Department of Oncology, University of Oxford, focusing on PRMT5's role in cancer. Gulsah is now a Post-Doctoral Scientist in the Department of Oncology at Oxford, specializing in T-cell exhaustion and cancer biology. An experienced mentor and lecturer, Gulsah has been awarded Fellowship of the Higher Education Academy (FHEA). She also co-leads MSc Applied Cancer Science module.
Recent publications
-
Sustained cancer-relevant alternative RNA splicing events driven by PRMT5 in high-risk neuroblastoma.
Bate-Eya LT. et al, (2024), Mol Oncol
-
The HDAC inhibitor zabadinostat is a systemic regulator of adaptive immunity.
Liu G. et al, (2023), Commun Biol, 6
-
Immune modulation underpins the anti-cancer activity of HDAC inhibitors.
Blaszczak W. et al, (2021), Mol Oncol, 15, 3280 - 3298
-
Antitumorigenic effect of memantine via interfering glutamate metabolism in mouse 4t1 breast tumor model
Albayrak G. et al, (2021), Anti-Cancer Agents in Medicinal Chemistry, 21, 1575 - 1580
-
Bortezomib synergizes with nocodazole in p53 mediated DNA damage response signalling in A549 lung cancer cells
Albayrak G., (2021), Journal of Research in Pharmacy, 25, 287 - 291